Davide Capodanno/X
Sep 4, 2025, 11:52
PARTHENOPE Trial: A New Benchmark in Risk Score Validation
Davide Capodanno, Professor of Cardiology at the University of Catania, editor-in-Chief of EuroIntervention, posted on X:
”I think I have a positive bias toward the PARTHENOPE trial, not only because I was part of the Steering Committee and deeply respect the work behind it, but also because it does something rarely done when validating risk scores: randomization. Usually, we see validation based on discrimination or area under the curve, but in reality, the true test of a score’s utility is whether randomization to a score-guided versus non–score-guided strategy makes a difference on clinical outcomes. Just think of how many scores we use every day that lack this kind of validation.”
Read more here.
Stay updated with Hemostasis Today.
-
Mar 10, 2026, 13:36Nirupama Yechoor: How Survivors of Stroke Define Spiritual Wellbeing in Recovery
-
Mar 10, 2026, 13:17Jeannie Devereaux: A Novel Technique for Precise High-Dose PRP Injection in Hip Labral Tear
-
Mar 10, 2026, 13:13Wolfgang Miesbach: Highlighting a Critical and Overlooked Dimension of Rare Bleeding Disorders in Women at EAHAD 2026
-
Mar 10, 2026, 13:08Michael Ertl: Honoured To Be Elected Fellow of the European Stroke Organisation
-
Mar 10, 2026, 13:00Nita Radhakrishnan: Benchmarking Hemophilia Care Across Global Income Settings Using Data from India
-
Mar 10, 2026, 12:59Hisam Siddiqi: Night Sweats Are Not Always a Hematological Plot Twist
-
Mar 10, 2026, 12:54Tzu-Fei Wang: Reassuring Real-World Data for Clinicians to Guide Anticoagulation in Prostate Cancer
-
Mar 10, 2026, 12:54RishiRaj Sinha: Connecting Researchers Driving the Future of Stem Cell Science at ISSCR 2026
-
Mar 10, 2026, 12:48Kayley Pappas: Translating Cutting-Edge Science Into Better Care and Hope for Stroke Patients at Mayo Clinic